EICHOR
● Active Not Recruiting
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
Condition: Advanced Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma · Sponsor: Ipsen
About this study
The purpose of the protocol, is to describe the use of cabozantinib tablets as monotherapy or in combination with nivolumab including the number of dose reductions, dose interruptions and terminations due to (serious) adverse events in subjects with advanced or metastatic renal cell carcinoma (mRCC) treated in real-life clinical setting in 1st line treatment.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (82)
| Landeskrankenhaus Hochsteiermark | Leoben, Austria | — |
| Kepler Universitätsklinikum GmbH | Linz, Austria | — |
| Uniklinikum Salzburg | Salzburg, Austria | — |
| Salzkammergutklinikum Vöcklabruck | Vöcklabruck, Austria | — |
| Klinikum Wels-Grieskirchen GmbH | Wels, Austria | — |
| Universitätsklinikum Aachen | Aachen, Germany | — |
| Urologisches Zentrum Euregio | Aachen, Germany | — |
| Onkologie aschaffenburg | Aschaffenburg, Germany | — |
| Universitätsklinikum Augsburg A.ö.R | Augsburg, Germany | — |
| MVZ Taunus GmbH | Bad Homburg, Germany | — |
| Hämatologisch-Onkologische Schwerpunktpraxis | Bad Liebenwerda, Germany | — |
| Urologische Praxis Bad Schlema | Bad Schlema, Germany | — |
+ 70 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03647878